Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019).

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019).

J Glob Antimicrob Resist. 2020 Oct 14;:

Authors: Shortridge D, Pfaller MA, Streit JM, Flamm RK

Abstract
OBJECTIVES: Delafloxacin is a broad-spectrum anionic fluoroquinolone with activity against Gram-positive and Gram-negative organisms, including methicillin-resistant Staphylococcus aureus. Both oral and intravenous formulations were approved for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to Gram-positive and Gram-negative organisms by the US Food and Drug Administration (2017) and European Medicines Agency (2019), and for community acquired bacterial pneumonia by FDA (2019). The SENTRY Antimicrobial Surveillance Program monitored the susceptibility of delafloxacin in the United States and Europe since 2014. The purpose of this study is to provide an update on delafloxacin activity against ABSSSI isolates primarily collected from hospitalized patients in Europe.
METHODS: A total of 11,866 nonduplicate isolates from ABSSSI were collected from 2014 to 2019 from 45 European medical centres in 24 countries. Susceptibilities were determined by broth microdilution. Results were interpreted using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (2020).
RESULTS: The most common isolate was S. aureus at 37.8% (n = 4,484), followed by Escherichia coli (11.0%) and Streptococcus spp. (10.0%). Delafloxacin susceptibility for S. aureus was 92.4% (MIC50/90, ≤0.004/0.25 mg/L); streptococci, 98.4%; and E. coli, 58.1%. Delafloxacin was more active against S. aureus than levofloxacin (84.0% intermediate; MIC50/90, 0.25/>4 mg/L) and moxifloxacin (88.3% susceptible; MIC50/90,≤0.06/2 mg/L). Susceptibility of E. coli was similar for the 3 quinolones.
CONCLUSIONS: Delafloxacin had broad-spectrum activity and improved potency against Gram-positive pathogens compared to levofloxacin and moxifloxacin. These data suggest that delafloxacin may be a useful therapeutic choice for the most common causes of ABSSSI.

PMID: 33068780 [PubMed - as supplied by publisher]